Basel, Switzerland

Petra Herzig



Average Co-Inventor Count = 17.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2011-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Petra Herzig: Innovator in Neurodegenerative Disorder Research

Introduction

Petra Herzig is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of neurodegenerative disorders through her innovative research and discoveries. With a total of two patents to her name, her work focuses on the detection and treatment of conditions such as Parkinson's disease and Alzheimer's disease.

Latest Patents

Herzig's latest patents include the KASPP (LRRK2) gene, which is crucial for the detection and treatment of neurodegenerative disorders. This invention refers to a newly discovered gene named KASPP, or Kinase Associated with Parkinsonism with Pleiomorphic Pathology, alternatively known as LRRK2, or Leucine-Rich Repeat Kinase 2. The patent details the gene's production, biochemical characterization, and its application in diagnosing and treating various neurodegenerative disorders, including sporadic Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and other related conditions.

Career Highlights

Throughout her career, Petra Herzig has worked with esteemed institutions such as Eberhard Karls Universität Tübingen and the Mayo Foundation for Medical Education and Research. Her research has significantly advanced the understanding of neurodegenerative diseases and their underlying genetic factors.

Collaborations

Herzig has collaborated with notable colleagues, including Thomas Meitinger and Tim Matthias Strom, contributing to a rich exchange of ideas and research findings in her field.

Conclusion

Petra Herzig's innovative work in the realm of neurodegenerative disorders highlights her dedication to advancing medical science. Her patents and collaborations reflect her commitment to improving the lives of those affected by these challenging conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…